Close Menu

NEW YORK — British liquid biopsy developer Angle reported on Thursday a 39 percent year-over-year drop in revenues for the first half of 2020 as the SARS-CoV-2 pandemic impacted use of its flagship Parsortix cell-sorting system.

For the six-month period ended June 30, Angle's revenues fell to £235,000 ($303,962) from £384,000, which the company attributed to the pandemic-related shutdown of research projects of many of its Parsortix customers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.